These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
379 related articles for article (PubMed ID: 34426442)
1. Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors. Takahashi S; Karayama M; Takahashi M; Watanabe J; Minami H; Yamamoto N; Kinoshita I; Lin CC; Im YH; Achiwa I; Kamiyama E; Okuda Y; Lee C; Bang YJ Clin Cancer Res; 2021 Nov; 27(21):5771-5780. PubMed ID: 34426442 [TBL] [Abstract][Full Text] [Related]
2. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors. Indini A; Rijavec E; Grossi F Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946310 [TBL] [Abstract][Full Text] [Related]
3. Trastuzumab deruxtecan for HER2+ advanced breast cancer. Lee J; Park YH Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373 [TBL] [Abstract][Full Text] [Related]
4. Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis. Suzuki M; Yagishita S; Sugihara K; Ogitani Y; Nishikawa T; Ohuchi M; Teishikata T; Jikoh T; Yatabe Y; Yonemori K; Tamura K; Hasegawa K; Hamada A Clin Cancer Res; 2021 Jul; 27(14):3970-3979. PubMed ID: 33980613 [TBL] [Abstract][Full Text] [Related]
5. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. Modi S; Park H; Murthy RK; Iwata H; Tamura K; Tsurutani J; Moreno-Aspitia A; Doi T; Sagara Y; Redfern C; Krop IE; Lee C; Fujisaki Y; Sugihara M; Zhang L; Shahidi J; Takahashi S J Clin Oncol; 2020 Jun; 38(17):1887-1896. PubMed ID: 32058843 [TBL] [Abstract][Full Text] [Related]
6. Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan. Yin O; Iwata H; Lin CC; Tamura K; Watanabe J; Wada R; Kastrissios H; AbuTarif M; Garimella T; Lee C; Zhang L; Shahidi J; LaCreta F Clin Pharmacol Ther; 2021 Oct; 110(4):986-996. PubMed ID: 33999422 [TBL] [Abstract][Full Text] [Related]
7. Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma: a pooled analysis of two phase I studies. Takahashi S; Bando H; Kinoshita I; Modi S; Tsurutani J; Bang YJ; Sato Y; Nakatani S; Lee C; Sugihara M; Okuda Y; Iwata H Jpn J Clin Oncol; 2024 Apr; 54(4):434-443. PubMed ID: 38231777 [TBL] [Abstract][Full Text] [Related]
8. Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2-Positive or HER2-Low Metastatic/Unresectable Breast Cancer. Shimomura A; Takano T; Takahashi S; Sagara Y; Watanabe J; Tokunaga E; Shinkai T; Kamio T; Kikumori K; Kamiyama E; Fujisaki Y; Saotome D; Yamashita T Clin Pharmacol Ther; 2023 Jan; 113(1):160-169. PubMed ID: 36164935 [TBL] [Abstract][Full Text] [Related]
9. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. Shitara K; Iwata H; Takahashi S; Tamura K; Park H; Modi S; Tsurutani J; Kadowaki S; Yamaguchi K; Iwasa S; Saito K; Fujisaki Y; Sugihara M; Shahidi J; Doi T Lancet Oncol; 2019 Jun; 20(6):827-836. PubMed ID: 31047804 [TBL] [Abstract][Full Text] [Related]
10. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803 [TBL] [Abstract][Full Text] [Related]
11. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Kumagai K; Aida T; Tsuchiya Y; Kishino Y; Kai K; Mori K Cancer Sci; 2020 Dec; 111(12):4636-4645. PubMed ID: 33051938 [TBL] [Abstract][Full Text] [Related]
12. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. Tsurutani J; Iwata H; Krop I; Jänne PA; Doi T; Takahashi S; Park H; Redfern C; Tamura K; Wise-Draper TM; Saito K; Sugihara M; Singh J; Jikoh T; Gallant G; Li BT Cancer Discov; 2020 May; 10(5):688-701. PubMed ID: 32213540 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice. Okamoto H; Oitate M; Hagihara K; Shiozawa H; Furuta Y; Ogitani Y; Kuga H Xenobiotica; 2020 Oct; 50(10):1242-1250. PubMed ID: 32306807 [TBL] [Abstract][Full Text] [Related]
14. Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. Bardia A; Krop IE; Kogawa T; Juric D; Tolcher AW; Hamilton EP; Mukohara T; Lisberg A; Shimizu T; Spira AI; Tsurutani J; Damodaran S; Papadopoulos KP; Greenberg J; Kobayashi F; Zebger-Gong H; Wong R; Kawasaki Y; Nakamura T; Meric-Bernstam F J Clin Oncol; 2024 Jul; 42(19):2281-2294. PubMed ID: 38652877 [TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of trastuzumab deruxtecan (T-DXd) in HER2-expressing solid tumours: a single-arm meta-analysis. Kou L; Chen X; Xie X; Wen Q; Li J; Li Y Jpn J Clin Oncol; 2023 Jul; 53(8):722-729. PubMed ID: 37114934 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys. Nagai Y; Oitate M; Shiozawa H; Ando O Xenobiotica; 2019 Sep; 49(9):1086-1096. PubMed ID: 30351177 [TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study). Dowling GP; Toomey S; Bredin P; Parker I; Mulroe E; Marron J; McLoughlin O; Teiserskiene A; Power C; O'Shea AM; Greally M; Morris PG; Duke D; Hill ADK; Hennessy BT BMC Cancer; 2024 Jan; 24(1):91. PubMed ID: 38233810 [TBL] [Abstract][Full Text] [Related]
18. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Siena S; Di Bartolomeo M; Raghav K; Masuishi T; Loupakis F; Kawakami H; Yamaguchi K; Nishina T; Fakih M; Elez E; Rodriguez J; Ciardiello F; Komatsu Y; Esaki T; Chung K; Wainberg Z; Sartore-Bianchi A; Saxena K; Yamamoto E; Bako E; Okuda Y; Shahidi J; Grothey A; Yoshino T; Lancet Oncol; 2021 Jun; 22(6):779-789. PubMed ID: 33961795 [TBL] [Abstract][Full Text] [Related]
19. Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study. Isogai A; Nozawa K; Nakakami A; Komaki R; Ozaki Y; Endo Y; Kataoka A; Kotani H; Yoshimura A; Hattori M; Sawaki M; Iwata H Breast Cancer Res Treat; 2024 Sep; 207(2):253-261. PubMed ID: 38797792 [TBL] [Abstract][Full Text] [Related]
20. Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer. Mishima S; Shitara K Expert Opin Biol Ther; 2021 Jul; 21(7):825-830. PubMed ID: 33798395 [No Abstract] [Full Text] [Related] [Next] [New Search]